GX China Biotech(02820.HK) down 0.56%, HUTCHMED in 1st-in-class trial

NewTimeSpace News: As of 13:33 HKT on September 28, 2026, GlobalX China Biotech(02820.HK) fell 0.56% intraday to HK$74.300, with turnover of HK$394,800 and a turnover rate of 0.06%.

NewTimeSpace understands that the ETF is managed by Mirae Asset Global Investments (Hong Kong) Limited and tracks the Solactive China Biotech Index, covering listed companies in China's biotech sector. As of 13:33 HKT on September 28, 2026, the ETF had assets of HK$704 million, a net asset value of HK$74.827 per unit and a board lot of 50 units.

On the news front, according to an announcement by HUTCHMED (00013.HK), the company initiated the Phase Ia portion of a global clinical trial of HMPL-A830 for unresectable advanced or metastatic solid tumours, with the first patient dosed in China on September 24; the drug is a first-in-class antibody-targeted conjugate combining a KRAS small-molecule inhibitor with an anti-EGFR antibody, and its subsidiary had reached an exclusive development and licence agreement with a GSK subsidiary granting rights to develop and commercialise the drug outside mainland China, Hong Kong, Macao and the Taiwan region of China. Separately, Biokin Pharmaceutical announced that three of its innovative drugs were included in the breakthrough therapy designation list by the Centre for Drug Evaluation of the National Medical Products Administration on September 27.

Industrial Securities noted in a research report that the global competitiveness of Chinese companies continues to strengthen and the strong momentum in licensing-out deals is expected to extend, with the rise of arrangements such as co-co development reflecting greater industry bargaining power; domestic policies continue to encourage innovation, and the sector is shifting from valuation-driven to being driven by earnings delivery and global commercialisation, with overseas pivotal trials, approvals and commercialisation milestones for already-licensed assets expected to be realised.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.